Form 4: Elevation Oncology Director Julie Cherrington Granted 35,000 Stock Options

Elevation Oncology, Inc. director Julie M Cherrington was granted 35,000 stock options with an exercise price of $0.3051, vesting over one year.

Summary

• Julie M Cherrington, a Director of Elevation Oncology, Inc. (ELEV), was granted 35,000 stock options.
• The options have an exercise price of $0.3051 per share.
• The grant date for these options was June 5, 2025.
• The options vest 100% on the one-year anniversary of the grant date, specifically June 5, 2026, provided Ms. Cherrington continues to provide service to the company.
• The options expire on June 4, 2035.
• Following this transaction, Ms. Cherrington beneficially owns 35,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive development as it aligns the director's interests with shareholders and is a standard practice for compensation, indicating stability in governance.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Negatives

• No immediate negative implications are apparent from this routine equity grant.

Risks

• The value of the stock options is subject to the future market price of Elevation Oncology's common stock, which may fluctuate.
• Vesting of the options is contingent upon the reporting person's continued service to the issuer.

Future Outlook

The stock options are set to vest on June 5, 2026, subject to the director's continued service, providing a future incentive for performance and potential equity ownership.

Industry Context

The grant of stock options to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages to align interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as a form of equity compensation for directors is a standard practice across publicly traded companies, particularly within the biotech sector, to incentivize long-term commitment and performance.
• The vesting schedule of 100% on the one-year anniversary is a common approach for director grants, ensuring continued engagement for at least a year post-grant.
• The exercise price of $0.3051, while specific to this grant, is typical for options granted at or near the market price on the grant date, though the document does not explicitly state the market price on that date.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing share value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest on June 5, 2026, contingent on continued service.
• The director may choose to exercise these options at any point after vesting and before the expiration date of June 4, 2035.

Key Dates

Recommendation

Keywords

Elevation Oncology, ELEV, Stock Options, Director Compensation, Equity Grant, Form 4, Insider Transaction, Beneficial Ownership